Revvity, the former life-sciences and diagnostics business of the company previously known as PerkinElmer, is stepping up ...

However, high-ticket life science instrumentation remains under pressure, necessitating a prudent 2025 outlook of 3%-5% organic growth. CFO Max Krakowiak shared that Revvity repurchased $185 ...

Revvity’s Life Sciences business declined 3% organically in the last reported quarter as weaker pharma/biotech demand and China headwinds, such as customers’ delayed purchases and pending ...

Revvity Inc (RVTY) reports robust Q4 results with 6% organic growth and a 30.3% adjusted operating margin, while navigating challenges in life science instrumentation. Life sciences company ...

Waltham, Massachusetts-based Revvity, Inc. (RVTY) is a global life sciences and diagnostics company specializing in innovative solutions for healthcare, research, and industrial applications.

In April 2023, it changed its name from PerkinElmer to Revvity. The firm has two business segments, namely: the Life Sciences Segment and the Diagnostics Segment. The Diagnostics Segment accounted ...

Revvity Inc (NYSE:RVTY) saw significant growth in its Life Science consumables, indicating a positive trend in pharma biotech customer behavior. The company successfully integrated recent ...

Proficio Capital Partners LLC lifted its position in Revvity, Inc. (NYSE:RVTY – Free Report) by 12,298.3% in the 4th quarter, ...

Subscribe for FREE Attendees can explore these technologies and more at Revvity’s booth (#1318), where over 40 products from its life sciences portfolio will be showcased. These include solutions for ...

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on ...